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BACKGROUND: Genome-wide association studies (GWASs) of major depressive disorder (MDD) have identiﬁed few
signiﬁcant associations. Testing the aggregation of genetic variants, in particular biological pathways, may be more
powerful. Regional heritability analysis can be used to detect genomic regions that contribute to disease risk.
METHODS: We integrated pathway analysis and multilevel regional heritability analyses in a pipeline designed to
identify MDD-associated pathways. The pipeline was applied to two independent GWAS samples [Generation
Scotland: The Scottish Family Health Study (GS:SFHS, N 5 6455) and Psychiatric Genomics Consortium (PGC:MDD)
(N 5 18,759)]. A polygenic risk score (PRS) composed of single nucleotide polymorphisms from the pathway most
consistently associated with MDD was created, and its accuracy to predict MDD, using area under the curve, logistic
regression, and linear mixed model analyses, was tested.
RESULTS: In GS:SFHS, four pathways were signiﬁcantly associated with MDD, and two of these explained a
signiﬁcant amount of pathway-level regional heritability. In PGC:MDD, one pathway was signiﬁcantly associated with
MDD. Pathway-level regional heritability was signiﬁcant in this pathway in one subset of PGC:MDD. For both
samples the regional heritabilities were further localized to the gene and subregion levels. The NETRIN1 signaling
pathway showed the most consistent association with MDD across the two samples. PRSs from this pathway
showed competitive predictive accuracy compared with the whole-genome PRSs when using area under the curve
statistics, logistic regression, and linear mixed model.
CONCLUSIONS: These post-GWAS analyses highlight the value of combining multiple methods on multiple GWAS
data for the identiﬁcation of risk pathways for MDD. The NETRIN1 signaling pathway is identiﬁed as a candidate
pathway for MDD and should be explored in further large population studies.
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Biohttp://dx.doi.org/10.1016/j.biopsych.2016.04.017Major depressive disorder (MDD) contributes 8.2% of the
global burden of disease (1). Twin studies have estimated
the narrow sense heritability of MDD to be 37%, conﬁrming the
involvement of genetic factors in MDD (2). However, published
genome-wide association studies (GWASs) of MDD have only
detected two loci associated with recurrent MDD at genome-
wide signiﬁcance in a study of Chinese women (3,4), despite
the success of GWASs for other psychiatric disorders (5).
Additional methods for detecting the aggregate effects of sub–
genome-wide signiﬁcant risk variants are required to better
extract information from available data.
Two lessons relevant to MDD can be learned from previous
studies of polygenic diseases. First, disease-associated var-
iants are enriched in functionally annotated regions of the
genome (6). Second, the small signals from individual genetic& 2016 Society of Biological Psychiatry. This is an open access a
CC BY license (http://creativecommons.org/licenses/by/4.0/).
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SEE COMMENTAvariants contrast with the stronger signals from individual
pathways (7). With the use of GWAS summary statistics, a
recent Psychiatric Genomics Consortium (PGC) study identi-
ﬁed disease-speciﬁc and shared pathways across multiple
psychiatric diseases (8). These ﬁndings suggest that the
cumulative effects from single variants converge on biological
pathways and that the pathways themselves may be more
tractable targets for GWASs. In the present study, we sought
to test whether the aggregate effects of low-penetrance
variants become detectable at the pathway level in MDD.
Various approaches have been developed to identify the
association between pathways and phenotype. Methods
designed to be applied to raw genotypes or summary
statistics of GWASs have been developed (9). The optimal
method should depend on the data type available and therticle under the
al ISSN: 0006-3223
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Psychiatryresearch goals. For instance, a pathway-based study demon-
strated the feasibility of identifying pathways and genes
associated with schizophrenia using analytic methods that
are designed for different data types (raw genotypes and
GWAS summary statistics) in three independent samples (10).
Genomic restricted maximum likelihood (GREML) analysis
methods (11) can be used to estimate the additive variance
contributed from all the genotyped single nucleotide poly-
morphisms (SNPs) by using linear mixed modeling (LMM).
They may also be adapted to further partition the variance
components by functionally annotated SNP categories
(11–13). Generally, for polygenic traits the proportion of the
phenotypic variance explained by the SNPs was proportional
to the number of SNPs involved (14). However, genomic
regions that explain more heritability than expected when
accounting for the number of SNPs they contain have been
uncovered. These regions usually overlap with regulatory,
genic, or conserved regions of the human genome
(12,13,15,16). The locally enriched heritability is deﬁned as
regional heritability. Regional heritability analysis can be
applied to identify genomic regions that contribute a signiﬁ-
cant proportion of heritability as an alternative association test
(17). With the use of this method, a recent study identiﬁed
more genomic regions that reached the suggestive level of
signiﬁcance than GWASs, suggesting that it is capable of
capturing some of the signals not detected by a single SNP
association test (18).
In this study, we sought to identify biological pathways
associated with MDD by making use of well-annotated molec-
ular pathway databases and two independent samples of
European ancestry. Each sample was run through a pipeline
in which a non–hypothesis-driven pathway analysis was applied
to identify MDD-associated pathways and that was followed by
multilevel regional heritability analyses to quantify and narrow
the genetic contribution from the candidate pathways. With the
use of this pipeline, we observed overlaps in the identiﬁed MDD
candidate pathways, genes, and subregions between samples.
Finally, to test for the predictive value of the pathway most
consistently associated with MDD across samples, we com-
pared the predictive accuracy of pathway-derived MDD poly-
genic risk score (PRS) to whole-genome–derived PRS.METHODS AND MATERIALS
The Tayside Research Ethics Committee (reference 05/S1401/
89) provided ethical approval for the study.
Data Sets
Generation Scotland: The Scottish Family Health
Study (GS:SFHS). This study included 21,387 subjects
(8772 men, 12,615 women; mean age, 47.2 years). Participants
were recruited from the registers of collaborating general
practices by their Community Health Index (19). A Structured
Clinical Interview for DSM-IV was used for the diagnosis of
MDD mood disorders (20) (Supplement). By the time we
performed this study, 9863 individuals were genotyped using
the Illumina (San Diego, CA) Human OmniExpressExome-8-
v1.0 array (21). Details of genotyping are described in detail
elsewhere (22). Quality control (QC) and imputation method areBiological Psycdescribed in the Supplement. In total, 592,690 genotyped and
2,163,848 imputed autosomal SNPs passed QC criteria and
were used in subsequent analyses. Because close relatives can
bias the pathway analysis and SNP heritability estimation, the
function “–grm-cutoff 0.025” in GCTA was used to remove one
of each pair of individuals with estimated relatedness larger
than 0.025 while maximizing the remaining sample size (11);
6455 subjects (1123 MDD case subjects; 5332 control subjects)
remained in the analyses described below.
PGC:MDD. The PGC provided summary statistics from the
GWAS mega-analysis of MDD from the discovery phase and
individual genotypes from the nine primary cohorts in this data
set. These data included 18,759 subjects of European ancestry
(9240 MDD case subjects; 9519 control subjects) (4). Case
subjects were required to have a diagnosis of DSM-IV lifetime
MDD (Supplement). Summary statistics included GWAS p values
and odds ratio information for 1,235,110 SNPs after imputation
using CEU+TSI HapMap3 data as reference (410 phased
haplotypes). We performed additional QC of these summary
statistics with inclusion thresholds info score $0.8, and minor
allele frequency $0.01, after which 1,074,100 SNPs remained
and were used in pathway analysis and polygenic risk proﬁling.
Imputed genotype data from nine PGC:MDD cohorts were
provided by PGC for the regional heritability analysis. Best-
guess imputed genotypes from each cohort were accepted at
the same level of QC as GS:SFHS. After removing one of each
pair of close relatives (t $ 0.025), the remaining 17,845
subjects were used in the downstream analyses (see
Supplemental Table S1 for sample information).
A Pipeline for Identiﬁcation of Pathways Associated
With MDD
This pipeline includes two stages of analyses: a pathway
analysis to identify MDD-associated pathways and multilevel
(pathway/gene/subregion) regional heritability analyses to nar-
row the signals of the association. The multilevel regional
heritability analyses for pathways identiﬁed by stage 1 were
tested on the same sample in which they were ﬁrst identiﬁed,
and the test statistics from stage 2 are therefore potentially
biased toward ﬁnding a more signiﬁcant association. However,
by applying the pipeline to two or more samples and by
seeking replication across these the pipeline could provide
independent replication of ﬁndings (as shown in the present
study). Further details of the pipeline are shown in Figure 1 and
Supplemental Table S2.
Stage 1: Pathway Analysis. For both samples, SNPs were
annotated to 1035 pathways (640 from Reactome [http://www.
reactome.org], 216 from BioCarta [http://cgap.nci.nih.gov/Path
ways/BioCarta_Pathways], and 179 from Kyoto Encyclopedia of
Genes and Genomes [http://www.genome.jp/kegg/]) (Suppl-
ement). For the GS:SFHS genotype data set (nSNP 5 592,690;
nsample 5 6455), the GRASS (gene set ridge regression in
association studies) algorithm (23) was used to identify pathway
MDD associations using only the genotyped SNPs (Supplement).
False discovery rate (FDR)-adjusted p values (nFDR 5 1035) were
calculated with the function p.adjust in the R package “stats”
(24,25). For the PGC:MDD GWAS summary results data set (nSNPhiatry February 15, 2017; 81:336–346 www.sobp.org/journal 337
Figure 1. The analytical pipeline, its application in identifying associated pathways with major depressive disorder (MDD) and its ﬁndings in two
independent samples: Generation Scotland: The Scottish Family Health Study (GS:SFHS) and Psychiatric Genomics Consortium (PGC:MDD). (A) Design of
the analytical pipeline. In the pipeline, pathway analysis was performed for 1035 pathways, signiﬁcant pathways were analyzed with multilevel regional
heritability analyses (RHAs) in the framework of genomic restricted maximum likelihood (GREML) analysis to quantify and localize the genetic effects on MDD.
In pathway analysis, GRASS was applied to the phenotype and genotype data of 6455 individuals from the GS:SFHS sample. MAGENTA was applied to the
summary data from PGC:MDD genome-wide association studies (GWASs) on 18,759 individuals. (B) The ﬁndings by the analytical pipeline in the two
samples. The NETRIN1 signaling pathway was identiﬁed as an associated pathway with MDD, and the association signals were localized to its gene DCC and
the subregion level. h2, heritability; Sig, signiﬁcant; SNP, single nucleotide polymorphism.
Pathway and Regional Heritability Analyses in MDD
Biological
Psychiatry= 1,074,100), MAGENTA (meta-analysis gene-set enrichment of
variant associations (26) was used to test for the enrichment of
genetic associations in each pathway for MDD, because only
summary statistics were available for this part of the study (http://
www.med.unc.edu/pgc/downloads), and MAGENTA was
designed to exploit summary data from GWAS results
(Supplement). MAGENTA reports a nominal p value and an
estimated FDR per pathway (nFDR 5 1035).
Stage 2: Estimation of MDD Phenotypic Variance
Explained by Imputed Genotypes of Regional SNPs
(Regional Heritability). Imputed SNPs were used in this
analysis to avoid underestimating the regional heritability (12). For
PGC:MDD, because of the heterogeneity caused by factors such
as different ancestry and clinical diagnosis across samples (4)
(Supplemental Table S1), as well as analyzing the regional
heritability in the combined data set, we performed the SNP
heritability analysis in the three subsets used by the PGC:MDD
consortium to group the nine cohorts (27) (Supplemental Table S1).
We applied GREML with LMM (11) to estimate the variance
explained by SNPs from genic regions of genes from candidate
pathways and the subregions of candidate genes. A log-likelihood
ratio test (LRT) was applied to test the signiﬁcance of the
estimated variance component (Supplement). Permutation analy-
sis was performed to test whether the pathway-level regional
heritability in candidate pathways was signiﬁcantly greater than
that expected by chance (Supplement). These analyses were338 Biological Psychiatry February 15, 2017; 81:336–346 www.sobp.operformed in GCTA (11). To map regional heritability at the
subregion level, regional heritability mapping (RHM; a modiﬁed
GREML analysis) was applied using a sliding window to scan
across the genic region of candidate genes (Supplement).
Polygenic Risk Proﬁling
PRSs (28) estimate the genetic risk of MDD for unrelated
individuals (nsample 5 6455) in GS:SFHS by adding the number
of risk alleles an individual had, weighted by the effect size
estimated in PGC:MDD (4) (Supplement).
To compare the PRS derived from the pathway SNPs to that
derived from the whole-genome SNPs, logistic regression and
LMMs were used to estimate the phenotypic variance explained
by PRSs. For logistic regression, PRS was treated as a ﬁxed
effect and MDD phenotype was regressed on PRS (other
covariates: age, age2, sex, top four principal components). The
variance explained by PRS was calculated as Nagelkerke’s R2 on
the observed scale (29). Permutation analysis was conducted to
set an empirical threshold by creating PRS from 1000 circularly
permuted SNP sets (30) that were then ﬁtted in logistic regression.
For LMM, we developed a PRS-bin-relationship matrix method in
which the MDD phenotype variation was explained by the PRS
similarity between subjects in the framework of LMM. The PRS
similarity reﬂects relatedness in terms of the MDD genetic risk.
The PRS similarity was treated as a random effect, and the
variance explained by this random effect was estimated with
REML and tested with LRT (Supplement).rg/journal
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curve (AUC) was calculated to determine the efﬁcacy of PRSs
in correctly classifying MDD case and control subjects using
equation 2 in Wray et al. (31).RESULTS
To identify candidate pathways for MDD, a pipeline that
combines pathway and multilevel (pathway/gene/subregion)
regional heritability analyses was applied to two independent
samples, GS:SFHS and PGC:MDD, respectively. Detailed
information of the analytical pipeline and the data usage is
shown in Figure 1 and Supplemental Table S2.
Identiﬁcation of MDD-Associated Pathways in GS:
SFHS
Pathway Analysis. By applying GRASS in GS:SFHS, four
pathways were signiﬁcantly associated with MDD after FDR
correction (nFDR 5 1035). These comprised the following: three
pathways from Reactome (MTORC1-mediated signaling,Table 1. Top 10 Pathways in Pathway Analysis for MDD Using
Rank Database Pathway p Value
GS:SFHS
1 BioCarta Feeder pathway 2.93E–05
2 Reactome ABCA transporters in lipid homeostasis 5.20E–05
3 Reactome NETRIN1 signaling 6.20E–05
4 Reactome MTORC1-mediated signaling 8.87E–05
5 BioCarta P35 Alzheimer’s pathway 2.69E–04
6 BioCarta SODD pathway 5.23E–04
7 Reactome Energy-dependent regulation of MTOR by
LKB1 AMPK
7.46E–04
8 Reactome NFKB activation through FADD RIP1
pathway mediated by caspase 8 and 10
7.47E–04
9 KEGG Taste transduction 6.48E–04
10 Reactome ABC family protein-mediated transport 8.68E–04
PGC:MDD
1 Reactome Role of second messengers in NETRIN1
signaling
1.00E–4
2 Reactome Defensins 9.00E–04
3 Reactome NRAGE signals death through JNK 1.50E–03
4 Reactome β Defensins 3.50E–03
5 Reactome Purine catabolism 1.26E–02
6 Reactome Formation of tubulin folding intermediates
by CCT TRIC
1.71E–02
7 BioCarta AKAP13 pathway 1.88E–02
8 Reactome Chondroitin sulfate dermatan sulfate
metabolism
5.54E–02
9 Reactome Elevation of cytosolic CA2 levels 5.67E–02
10 Reactome Opsins 4.30E–02
nFDR 5 1035.
Eff, effective; Exp No. Genes .95% Cutoff, expected number of genes
false discovery rate; GS:SFHS, Generation Scotland: The Scottish Family He
major depressive disorder; Obs No. Genes .95% Cutoff, observed numbe
cutoff; PGC, Psychiatric Genomics Consortium.
aFor GRASS results on GS:SFHS, four pathways yielded signiﬁcance af
yielded signiﬁcance after FDR correction.
Biological PsycNETRIN1 signaling, ABCA transporters in lipid homeostasis)
and one pathway from BioCarta (Feeder pathway) (Table 1).
Regional Heritability Analysis. With the use of GREML,
the estimate of h2g (the heritability explained by all GWAS SNPs)
for MDD was 0.25 (SE 5 0.10) in GS:SFHS (Supplemental Table
S4A). To further investigate the regional heritability captured by
SNPs from pathways that were signiﬁcant in pathway analysis,
for each pathway, we partitioned the genome-wide SNPs into
two sets as follows: SNPs from the pathway and the remaining
SNPs. We then jointly estimated their contribution to MDD
phenotypic variance in LMM. Among the four pathways that
were signiﬁcant in pathway analysis, two yielded signiﬁcant
p values (after FDR adjustment, nFDR 5 4) based on the LRT for
pathway-level regional heritability in MDD, with the highest
regional heritability estimated in the NETRIN1 signaling pathway
[pathway-level regional heritability attributable to the pathway
SNPs (h2RÞ 5 0.014, SE 5 0.009, plrt_FDR 5 .019] (Table 2).
Permutation test across the circularly permuted SNP sets with
the same set size for the two pathways showed that the
detected pathway regional heritability was not attributable to
gene set size and linkage disequilibrium (LD) structuresGRASS on GS:SFHS and Using MAGENTA on PGC:MDD
pFDR
Eff Gene
Size
Exp No. of Genes
.95% Cutoff
Obs No. of Genes
.95% Cutoff
2.14E–02a — — —
2.14E–02a — — —
2.14E–02a — — —
2.30E–02a — — —
5.58E–02 – — —
8.59E–02 — — —
8.59E–02 — — —
8.59E–02 — — —
8.59E–02 — — —
8.98E–02 — — —
1.46E–02a 8 0 4
2.04E–01 25 1 6
2.07E–01 36 2 7
2.75E–01 21 1 5
3.11E–01 10 1 3
6.67E–01 22 1 4
7.31E–01 12 1 3
7.41E–01 49 2 5
7.43E–01 10 0 2
7.46E–01 10 0 2
with a corrected gene p value .95 percentile enrichment cutoff; FDR,
alth Study; KEGG, Kyoto Encyclopedia of Genes and Genomes; MDD,
r of genes with a corrected gene p value .95th percentile enrichment
ter FDR correction. For MAGENTA results on PGC:MDD, one pathway
hiatry February 15, 2017; 81:336–346 www.sobp.org/journal 339
Table 2. Pathway-Level Regional Heritability Analysis Results for the Signiﬁcant Pathways Identiﬁed in Pathway Analysis for
GS:SFHS and PGC:MDD
Pathway or Group h2R
SE
(h2R) h
2
C
SE
(h2C)
LRT (h2R)
p Value
LRT (h2R)
pFDR npathway SNPs
%
SNP
%
h2GWAS
%h2GWAS/
%SNP
GS:SFHS
Reactome MTORC1-mediated signaling 0.006 0.004 0.240 0.099 7.70E–03 1.86E–02a 947 0.04 2.40 54.84
Reactome NETRIN1 signaling 0.014 0.009 0.224 0.099 9.28E–03 1.86E–02a 8809 0.41 5.80 14.20
BioCarta feeder pathway 0.004 0.004 0.251 0.099 3.77E–02 5.03E–02 507 0.02 1.00 42.68
Reactome ABCA transporters in lipid
homeostasis
0.000 0.004 0.251 0.099 5.00E–01 5.00E–01 1020 0.05 0.00 0.00
PGC:MDD: Role of Second Messengers In NETRIN1 Signaling
PGC:MDD combined 0.0001 0.0006 0.2616 0.0216 3.77E–01 4.17E–01 1083 0.001 0.0005 0.52
PGC:MDD subset 1 0.0055 0.0034 0.2625 0.0596 9.06E–03 3.62E–02a 1083 0.001 0.0193 19.12
PGC:MDD subset 2 0.0010 0.0018 0.4655 0.0525 2.56E–01 4.17E–01 1083 0.001 0.0034 3.37
PGC:MDD subset 3 0.0004 0.0022 0.4442 0.0780 4.17E–01 4.17E–01 1083 0.001 0.0014 1.41
FDR, false discovery rate; GS:SFHS, Generation Scotland: The Scottish Family Health Study; GWAS, genome-wide association study;
h2C; heritability attributable to the complement SNP set; h
2
R, pathway-level regional heritability attributable to the pathway SNPs; LRT, log-
likelihood ratio test; LRT (h2R) p value and LRT (h
2
R) pFDR, nominal p value and FDR-adjusted p value from LRT for h
2
R; npathway SNPs, SNP
number in the pathway; PGC:MDD, Psychiatric Genomics Consortium Major Depressive Disorder; SNP, single nucleotide polymorphism;
%h2GWAS/%SNP, the ratio of the percentage of h
2
gwas in pathway to the percentage of SNPs in the pathway.
aSigniﬁcant results after multiple test correction (5%).
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Psychiatry(NETRIN1 signaling: pperm 5 .018; MTORC1-mediated signaling
pathway: pperm 5 .01) (Supplement).
To narrow the signals from the two pathways in which
signiﬁcant pathway-level regional heritability was detected,
gene-level regional heritability was estimated for single genes
in the two pathways. The heritabilities for three genes (DCC,
UNC5D, and SIAH2) from the NETRIN1 pathway and one gene
(RPTOR) from the MTORC1-mediated signaling pathway
obtained nominal signiﬁcance in LRT (Supplemental Table
S5A). Among them, the receptor proteins encoded by DCC
and UNC5D share the same ligand, Netrin-1, a key signaling
molecule in the NETRIN signaling pathway (32). To ﬁne-map the
regional heritability within the two receptor genes and to further
explore if any of the subregions that conferred heritability over-
lapped with any functional domains, RHM was applied to the two
genes using a ﬁxed sliding window to scan across their genic
regions (Figure 2, Supplemental Figure S1). Block 6 in DCC and
Block 1 in UNC5D yield signiﬁcance in LRT (Block6DCC: plrt_bonf
5 .021; Block1UNC5D: plrt_bonf 5 .028) (Supplemental Table S6A).
Block 6 in DCC overlapped with the fourth immunoglobulin-like
domain (Figure 2) (33). Block 1 in UNC5D overlapped with
H3K4me3 signal region (Supplemental Figure S1) (34).
Identiﬁcation of MDD-Associated Pathways in PGC:
MDD
Pathway Analysis. With the use of MAGENTA, only one
pathway from Reactome [role of second messengers in NETRIN1
signaling, which is a subset of the “the NETRIN1 signaling
pathway” (100% overlap) (35)] was identiﬁed as associated with
MDD after FDR correction (nFDR 5 1035) (Table 1).
Regional Heritability Analysis. Following the PGC pub-
lished study, data from nine cohorts were grouped into three
subsets for the GREML analysis (27) (Supplemental Table S1).
The estimate of h2g for MDD varied from 0.26 (SE5 0.06) to 0.47
(SE 5 0.05) across subsets (Supplemental Table S4B). The
pathway-level regional heritability from the role of second340 Biological Psychiatry February 15, 2017; 81:336–346 www.sobp.omessengers in the NETRIN1 signaling pathway was nominally
signiﬁcant using LRT in subset 1 (plrt 5 .017, plrt_FDR 5 .07),
whereas it was not signiﬁcant in subset 2, subset 3, and the
combined set (Table 2). Permutation test across the circularly
permuted SNP sets with the same set size in subset 1 conﬁrmed
the enrichment of SNP heritability in this pathway (pperm 5 .01)
(Supplement). The gene-level regional heritability analysis for this
pathway obtained nominal signiﬁcance in one gene (DCC,
plrt 5 .02) in subset 1, no genes in subset 2, one gene (TRPC3)
in subset 3, and two genes (PLCG1 and PITPNA) in the
combined data set (Supplemental Table S5B). Because in
subset 1 the pathway-level regional heritability was signiﬁcant
for the role of second messengers in the NETRIN1 signaling
pathway and the gene-level regional heritability was signiﬁcant
in the DCC gene, we further localized the regional heritability by
applying RHM to DCC in subset 1 (Supplemental Table S6B).
The distribution of the regional heritability for the DCC gene in
subset 1 was similar to that obtained in GS:SFHS (Figure 2).
Replication of GS:SFHS Results in PGC:MDD and
PGC:MDD Results in GS:SFHS
Among the four pathways identiﬁed by pathway analysis in
GS:SFHS, the NETRIN1 signaling pathway was replicated in
PGC:MDD (ppath 5 .010, nbonf 5 4 1 1 5 5, ppath_bonf 5 .05),
whereas the other three pathways failed to replicate (Table 3).
For the regional heritability analysis, among the two signiﬁcant
pathways in GS:SFHS, the NETRIN1 signaling pathway was
signiﬁcant in LRT in PGC:MDD subset 1 (plrt 5 .00258, nbonf 5
2 3 (1 1 3) 1 1 5 9, plrt_bonf 5 .02) but was not signiﬁcant in
other subsets or in the combined set (Table 4). The MTORC1-
mediated signaling pathway failed to replicate in all subsets
and in the combined set (Table 4). The gene-level regional
heritability of DCC was nominally signiﬁcant in both GS:SFHS
(Supplemental Table S5A) and in subset 1 in PGC:MDD
(Supplemental Table S5B). The signiﬁcant block 6 of DCC
that was detected in GS:SFHS was fully covered by the
nominally signiﬁcant blocks in subset 1 (Figure 2).rg/journal
Figure 2. Genic region in DCC showing blocks used in REACTA on Generation Scotland: The Scottish Family Health Study (GS:SFHS) and subset 1 in
Psychiatric Genomics Consortium Major Depressive Disorder (PGC:MDD) subset 1 (subsets 2 and 3 failed to obtained signiﬁcance in the pathway-level regional
heritability of NETRIN1 signaling pathway). In GS:SFHS, the sliding window [window size 5 200 single nucleotide polymorphisms (SNPs)] deﬁned 9 blocks with
average block size of 179 kb. In PGC:MDD subset 1, window size of 100 SNPs was used, as the density of SNPs in PGC:MDD data set was approximately one
half of that in GS:SFHS. This divided DCC into 8 blocks with average block size of 191 kb. Blue bar indicates insigniﬁcant region in log-likelihood ratio test (LRT);
orange bar, signiﬁcant region in LRT; red bar, signiﬁcant region in LRT after Bonferroni correction; red dotted line, signiﬁcant Block 6 in GS:SFHS, which overlaps
with the fourth immunoglobulin-like (Ig) domain. This region was fully covered by the nominal signiﬁcant regions in subset 1 in PGC:MDD.
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MDD, the role of second messengers in NETRIN1 signaling
pathway, was nominally signiﬁcant in pathway analysis in GS:
SFHS (ppath 5 .018, nbonf 5 5, ppath_bonf 5 .09) (Table 3). For
the regional heritability analysis, this pathway was nominally
signiﬁcant in LRT in GS:SFHS (plrt 5 .017, nbonf 5 9, plrt_bonf 5
.156) (Table 4).Table 3. Replication Results of Pathway Analysis
Database Pathway p Valu
GS:SFHS in PGC:MDD
Reactome ABCA transporters in lipid homeostasis 5.39E–
Reactome NETRIN1 signaling 9.90E–
Reactome MTORC1-mediated signaling 4.05E–
BioCarta Feeder pathway 1.00E1
PGC:MDD in GS:SFHS
Reactome Role of second messengers in NETRIN1 signaling 1.75E–
Four pathways were identiﬁed from GS:SFHS in PGC:MDD, and one pa
Eff, effective; Exp No. Genes .95% Cutoff, expected number of genes
SFHS, Generation Scotland: The Scottish Family Health Study; Obs No. G
p value .95th percentile enrichment cutoff; pbonf, adjusted p value using B
Consortium Major Depressive Disorder.
aSigniﬁcant results after multiple test correction (5%).
Biological PsycEstimating the Predictive Accuracy of PRSs Derived
From SNPs in the NETRIN1 Signaling Pathway or the
Whole Genome
We applied polygenic risk proﬁling to measure the additive genetic
effect from the NETRIN1 signaling pathway and compared it with
that from the whole genome (Methods and Materials).e pbonf
Eff Gene
Size
Exp No. Genes
.95% Cutoff
Obs No. Genes
.95% Cutoff
01 1.00E100 15 1 1
03 4.95E–02a 37 2 6
01 1.00E100 10 1 1
00 1.00E100 9 0 0
02 8.76E–02 — — —
thway was identiﬁed from PGC:MDD in GS:SFHS. nbonf 5 5.
with a corrected gene p value .95th percentile enrichment cutoff; GS:
enes .95% Cutoff, observed number of genes with a corrected gene
onferroni multiple testing correction; PGC:MDD, Psychiatric Genomics
hiatry February 15, 2017; 81:336–346 www.sobp.org/journal 341
Table 4. Replication Results of Pathway-Level Regional Heritability Analysis
NETRIN1 Signaling MTORC1-Mediated Signaling
h2R SE (h
2
R) h
2
C SE (h
2
C)
LRT (h2R)
p Value
LRT (h2R)
pbonf h
2
R SE (h
2
R) h
2
C SE (h
2
C)
LRT (h2R)
p Value
LRT (h2R)
pbonf
GS:SFHS in PGC:MDD: Group
Combined 0.000 0.001 0.262 0.022 4.75E–01 1.00E100 0.0003 0.0005 0.2843 0.0220 2.71E-01 1.00E100
Subset 1 0.014 0.006 0.256 0.059 2.59E–03 2.33E–02a 0.0006 0.0015 0.2647 0.0597 3.32E-01 1.00E100
Subset 2 0.003 0.004 0.463 0.052 1.59E–01 1.00E100 0.0018 0.0019 0.4643 0.0524 1.02E-01 9.17E–01
Subset 3 0.002 0.005 0.443 0.078 3.83E–01 1.00E100 0.0000 0.0018 0.4447 0.0781 5.00E-01 1.00E100
PGC:MDD in GS:SFHS: Pathway
Reactome role of second
messengers in NETRIN1 signaling
— — — — — — 0.005 0.004 0.235 0.099 1.73E-02 1.56E–01
Two pathways were signiﬁcant in GS:SFHS in PGC:MDD, and one pathway was signiﬁcant in PGC:MDD in GS:SFHS. nbonf 5 9.
GS:SFHS, Generation Scotland: The Scottish Family Health Study; h2C; heritability attributable to the complement SNP set; h
2
R, pathway-level
regional heritability attributable to the pathway SNPs; LRT, log-likelihood ratio test; LRT (h2R) pbonf, adjusted p value from LRT for h
2
R using
Bonferroni multiple testing correction; LRT (h2R) p value, nominal p value from LRT for h
2
R; PGC:MDD, Psychiatric Genomics Consortium Major
Depressive Disorder.
aSigniﬁcant results after multiple test correction (5%).
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PsychiatryWith the use of logistic regression, for both pathway and
whole-genome SNP sets, PRSs created without LD clump-
ing explained a higher proportion of variance than PRSs
created with LD clumping (Supplemental Table S7,
Figure 3). The PRS created from the whole-genome SNPs
explained a maximum MDD variance of 0.198% (GWAS
pcutoff 5 .2, without LD clumping; pt-test 5.006). The PRS
created from SNPs in the NETRIN1 signaling pathway
explained a maximum variance of 0.216% (GWAS pcutoff 5
.2, without LD clumping; pt-test 5 .004) (Supplemental Table
S7). Permutation test across the circularly permuted SNP sets
with the same set size suggested that the variance explained by
the NETRIN1 signaling pathway PRS (without LD clumping) in
the logistic regression model was signiﬁcantly higher than
expected by chance (Supplemental Table S8).Figure 3. The phenotypic variance explained by polygenic risk score (PRS) a
disequilibrium (LD) clumping: the average Nagelkerke’s R2 of 1000 PRSs crea
circular permuted SNP sets with the same set size). GWAS, genome-wide asso
342 Biological Psychiatry February 15, 2017; 81:336–346 www.sobp.oWith the use of LMM, we estimated the proportion of MDD
variance explained by pairwise MDD-PRS similarity between
individuals. A PRS-bin-relationship variance-covariance matrix
was constructed and jointly ﬁtted with a SNP-based genomic-
relationship matrix (GRM) in LMM. For each PRS, multiple bin
numbers were tested to assess the stability of the model
across different bin settings. When the comparison was
between the PRSs created without LD clumping, the PRS-
bin-relationship matrices created from the NETRIN1 signaling
pathway outperformed those created from the whole-genome
set because they consistently explained a signiﬁcant propor-
tion of variance across multiple bin settings and p value
thresholds (Figure 4), with an explained maximum MDD
variance of 1.7% (SE 5 0.02, plrt 5 .013, pperm 5 .012; PRS
setting: bin 5 50, GWAS pcutoff 5 .5) (Supplemental Table S9).s a ﬁxed effect in logistic regression. Perm Aver NETRIN1 without linkage
ted from permuted pathway single nucleotide polymorphisms (SNPs) (the
ciation study.
rg/journal
Figure 4. The log-likelihood ratio test (LRT) result from linear mixed modeling to show the signiﬁcance level of the phenotypic variance explained by
polygenic risk score-bin-relationship matrices derived from variants in whole genome and the NETRIN1 signaling pathway with or without linkage
disequilibrium (LD) clumping at genome-wide association study p value thresholds of .2, .5, and 1, using different bins. The color of the bars was designated
by the bin number. Red line marks the signiﬁcance level (plrt 5 .05).
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PsychiatryNonetheless, for PRSs created with LD clumping, most of the
PRS-bin-relationship matrices, created both from the whole-
genome SNPs and from the pathway SNPs, failed to obtain
signiﬁcance in LRT, with three exceptions at low-bin-setting
(bin 5 10, 20, 50) for the whole-genome PRS-bin-relationship
matrix (Figure 4), the maximum MDD variance explained is
2.47% (SE 5 0.028, plrt 5 .028, pperm 5 .021; PRS setting:
bin 5 10, GWAS pcutoff 5 .2) (Supplemental Table S9). When
jointly ﬁtting PRS-bin-relationship matrices from the pathway
and whole genomes as well as a GRM in LMM, the variance
explained by the NETRIN1 pathway PRS (without LD clump-
ing) remained stable and signiﬁcant (Supplemental Table S10).
Finally, the estimation of the AUC receiver-operating char-
acteristic suggested that in general the AUCs of MDD PRSs
were low, ranging from 0.498 to 0.532, with the NETRIN1
PRS obtaining the highest AUC (AUCNETRIN1_max 5 0.532,
AUCwhole_max 5 0.527) (Supplemental Table S11).DISCUSSION
Typically, disease-associated pathways have been assumed
to have the following features: 1) the genetic variants in them
are shown to be associated with disease in association tests,
2) the genetic variants in them explain a signiﬁcant proportion
of phenotypic variance, and 3) the genetic proxies such as
PRSs derived from them have valuable predictive power for
the disease. Here, we applied a pipeline that integrates path-
way analysis and regional heritability analyses to two inde-
pendent samples. This enables the identiﬁcation of candidateBiological Psycpathways for MDD that address the ﬁrst two features. By
comparing results from each stage of the pipeline, we
identiﬁed the NETRIN1 signaling pathway, which has multilevel
associations with MDD that are observed across samples.
Finally, the polygenic risk proﬁling method provided additional
evidence that this pathway also satisﬁed the third feature.
In the pathway analysis, we identiﬁed four MDD-associated
pathways in GS:SFHS but only one in PGC:MDD by using two
methods, GRASS and MAGENTA, respectively, because dif-
ferent data types were available from each data set for this
analysis (Supplement). No pathway was associated with MDD
in both GS:SFHS and PGC:MDD. However, the only associ-
ated pathway detected by MAGENTA in PGC:MDD, the role of
second messengers in the NETRIN1 signaling pathway, was a
subset of the NETRIN1 signaling pathway (100% overlap) that
was detected by GRASS in GS:SFHS. Previous studies have
suggested that the NETRIN1 signaling pathway plays a crucial
role in axon guidance, a process that establishes precise brain
circuits during the development of the central nervous system
(36). Interestingly, in the development stage of the thalamus,
the response of embryonic thalamocortical axons to the
NETRIN1 signaling is modulated by serotonin signaling, a
system that has been repeatedly implicated in the cause of
MDD (37,38). Given these convergent lines of research,
NETRIN1 signaling is a promising candidate pathway for MDD.
The pathway analysis was followed by a pathway-level
regional heritability analysis. We found that in both samples
some of the MDD-associated pathways, including the two
NETRIN1 signaling pathways, contributed signiﬁcantly tohiatry February 15, 2017; 81:336–346 www.sobp.org/journal 343
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Psychiatryexplain MDD variance. Moreover, the pathway-level regional
heritability estimated was greater than expected, given the SNP
set size in these pathways (Table 2), suggesting an enrichment
of heritability further supported by the permutation test. These
results were consistent with previous studies reporting enrich-
ment of heritability in functionally annotated regions (12,13).
In the NETRIN1 signaling pathway, key proteins affect axon
guidance; DCC is the key receptor for the attractive response
to Netrin-1, whereas UNC5, alone or together with DCC, is
associated with the repulsive response to Netrin-1 (36,39). In
our study, the gene-based regional heritability analyses sug-
gested that DCC and UNC5D were among the most associ-
ated genes in GS:SFHS, which is consistent with their
functional importance in the NETRIN1 signaling pathway. In
PGC:MDD, DCC was the only gene that attained nominal
signiﬁcance (in subset 1, the only subset for which the
pathway-level regional heritability from the candidate pathway
is signiﬁcant). When applying RHM to DCC, the regional
heritability was localized to block 6 in GS:SFHS (for PGC:
MDD subset 1 this region also obtains nominal signiﬁcance)
(Figure 2). Block 6 overlapped with the fourth immunoglobulin-
like domain (Figure 2), which may be necessary for the axonal
attraction mediated by Netrin-1 and draxin (40). A recent meta-
analysis of GWASs for depressive symptom (N 5180,886)
reported that one locus (rs62100776) from the same gene
DCC exceeded genome-wide signiﬁcance (it includes subjects
from PGC:MDD, but the major source of sample is from UK
biobank [nukb = 105,739]) (41). This SNP is located in block 7,
which is adjacent to the signiﬁcant block 6 and is nominally
signiﬁcant in our study (Figure 2). This overlapped ﬁnding, using
a much larger sample size, validated our results and indirectly
supported the value of applying our pipeline in studies with small
sample size. The signiﬁcant block in UNC5D overlapped with an
H3K4me3 modiﬁcation, which implicates an active promoter in
that region (42). These results imply a potentially functional
contribution of variants in DCC and UNC5D to MDD.
The pathway identiﬁed with our pipeline accounts for a
signiﬁcant proportion of phenotypic variance, which is an
attractive feature for a biomarker. PRSs were created by
adding the genetic effects among biomarkers. Although
MDD is a highly polygenic disorder, PRSs from whole-
genome SNPs can be noisy because they include SNPs with
no effect on MDD. A more accurate prediction is likely from
scores derived from biomarkers with a higher proportion of
causal SNPs. We thus measured the prediction value for MDD
of the PRSs derived from the associated NETRIN1 signaling
pathway. The results showed that pathway PRSs explain a
higher proportion of phenotypic variance than whole-genome
PRSs, when PRS was ﬁtted as a ﬁxed effect in the logistic
regression. The AUC statistics also support a better prediction
by the pathway PRSs. In addition, we developed a PRS-bin-
relationship matrix method in which PRS similarity was used to
explain phenotypic variation of MDD in LMM. With the use of
this method, the MDD phenotypic variance explained by the
pathway PRS and whole-genome PRS was substantially
increased to 1.70% and 2.47%, respectively. Although the
largest variance explained by the pathway PRS was smaller
than the whole-genome PRS, the pathway PRS performed
better in terms of the signiﬁcance level in LRT across most of
the tested bins (Figure 4).344 Biological Psychiatry February 15, 2017; 81:336–346 www.sobp.oNotably, although the PRS-bin-relationship matrix is con-
ceptually similar to the classic common SNP-based GRM, a
key difference was that the PRS-bin-relationship matrix took
the information of the effect size of loci as estimated in the
discovery sample, PGC:MDD, and the genotypes from the
target sample, GS:SFHS, so that it measures the MDD genetic
risk similarity and the interpretation of the model which it ﬁtted
was across samples. This method also enabled the discrim-
ination of genetic effects represented in the pathway PRS,
whole-genome PRS, and GRM when they were jointly ﬁtted in
LMM. Our results suggest that they explained distinct pro-
portions of phenotypic variance (1.6% for pathway PRS, 2.2%
for whole-genome PRS, and 22.7% for whole-genome GRM)
(Supplemental Table S10).
With regard to limitations and further research, ﬁrst, differ-
ent methods were applied in different samples that used
different data formats in the pathway analysis. This may have
inﬂuenced the consistency and the comparability of the results
and may have complicated their interpretation. Second, it is
possible that the predictive accuracy of the NETRIN1 signaling
pathway measured in this study is inﬂated, because both
samples were involved in the pipeline where this pathway was
identiﬁed (albeit independently); further replication in inde-
pendent populations would strengthen our ﬁndings. Note that
although the multilevel regional heritability analyses enable the
ﬁne-mapping of association signals, their p values may be
inﬂated because the ﬁne-mapping was conducted at the same
data sets where the pathways were identiﬁed. We therefore
suggest a careful interpretation of the LRT results from the
regional heritability analyses, and we attach more importance
to the comparisons of the regional heritability patterns across
populations (Figure 2). Third, the route by which NETRIN1
signaling pathway contributes to MDD is unknown. Future
directions for increasing our understanding could include
exploring mutant DCC animal models of MDD and testing
the interactions of NETRIN1 receptors with known MDD-
associated proteins.
In summary, this study shows that the NETRIN1 signaling
pathway was associated with MDD in two independent samples.
Variants in this pathway accounted for a signiﬁcant proportion of
variance in susceptibility for MDD and have valuable prediction
power. These ﬁndings further support a role for NETRIN1 in the
cause of MDD and provide a basis for future studies.ACKNOWLEDGMENTS AND DISCLOSURES
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